<DOC>
	<DOCNO>NCT00783510</DOCNO>
	<brief_summary>This global registry , evaluate long-term safety Humira® patient moderate severe polyarticular Juvenile Idiopathic Arthritis ( JIA ) , treat recommended Humira® product label . Patients treat MTX consider reference group . Patients follow Humira® Methotrexate ( MTX ) arm 10 year enrollment date one treatment arm .</brief_summary>
	<brief_title>Juvenile Idiopathic Arthritis ( JIA ) Registry</brief_title>
	<detailed_description>This registry assess incidence rate Humira ( monotherapy combination therapy MTX ) MTX observational treatment-emergent SAEs , Adverse Events Special Interest ( AESI ) Pregnancy patient diagnose moderately severely active polyarticular polyarticular-course JIA Year 5 . From Year 6 Year 10 SAEs , subset AESI include congestive heart failure ( CHF ) , malignancy , AEs least possibly relate and/or leading discontinuation registry treatment pregnancy collect . For JIA patient 2 &lt; 4 year age country available local approval group patient time consent registry , emergent AESI , SAEs pregnancy ( age patient become pregnant ) collect full 10 year . The approved age range HUMIRA U.S. , European Union ( EU ) Australia 4 year age old , recent approval EU JIA patient 2 &lt; 4 year age . Patients discontinue registry 10 year offer participate direct Health Care Provider follow-up process , allow local regulation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>For patient enrol HUMIRA® arm ; pediatric patient diagnose time moderately severely active polyarticular polyarticularcourse JIA ( define arthritis affect &gt; = 5 joint time diagnosis polyarticular polyarticularcourse JIA ) prescribe HUMIRA® therapy accord local approve HUMIRA® product label meet one follow criterion : Enrolled patient 4 17 year age per approve HUMIRA® product label addition JIA patient 2 &lt; 4 year age country available local approval group patient time consent registry . Newly initiate ( within 24 month registry entry ) HUMIRA® therapy receive continuous ( 70 consecutive day drug ) HUMIRA® therapy , physician provide available source documentation SAEs , AEs Special Interest , dose information since initiation therapy ; Or enter participation ( within 24 month registry entry , long , continuously treat site ) AbbVie Humira sponsor study , regardless age number joint symptoms JIA , receive continuous ( 70 consecutive day drug ) HUMIRA® therapy physician provide available source documentation SAEs , AEs Special Interest , dose information since initiation therapy . For patient enrol MTX arm ; pediatric patient diagnose time moderately severely active polyarticular polyarticularcourse JIA ( define arthritis affect &gt; = 5 joint time diagnosis polyarticular polyarticularcourse JIA ) prescribe MTX therapy alone combination disease modify antirheumatic drug ( DMARDs ) accord local product labeling ( initiated treatment within 24 month registry entry ) receive continuous therapy physician available provide source documentation SAEs , AEs Special Interest , dose information since initiation therapy . Patients treat MTX arm registry prematurely discontinue MTX arm due nonresponder , become intolerant MTX treatment need combination treatment HUMIRA® therapy may eligible enroll HUMIRA® treatment arm ongoing AEs/SAEs resolve , meet inclusion criterion enroll within registry enrollment period . In case ongoing AEs/SAEs time treatment arm switch , AbbVie Designated Physician contact assess eligibility patient roll Humira treatment arm . Parent guardian voluntarily sign date informed consent/patient authorization form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) applicable accord local law , nature registry explain patient 's parent legal guardian opportunity ask question . Pediatric patient include discussion per applicable local regulation order obtain verbal write assent . Patients enrol HUMIRA® Methotrexate ( MTX ) arm prescribe treated accordance approve local HUMIRA® and/or local MTX product label Patients enrol HUMIRA® MTX arm require ongoing treatment Kineret® ( anakinra ) , Orencia® ( abatacept ) , Rituxan® ( rituximab ) , Enbrel® ( etanercept ) , Remicade® ( infliximab ) , approve biologic agent investigational agent . Patients enrol MTX arm prior treatment investigational agent antirheumatic biologic therapy , limited , Orencia® ( abatacept ) , Enbrel® ( etanercept ) , Remicade® ( infliximab ) , Rituxan® ( rituximab ) , Actemra® ( tocilizumab )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Polyarticular JIA</keyword>
	<keyword>Juvenile Arthritis</keyword>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>JIA</keyword>
	<keyword>Polyarticular-course JIA</keyword>
</DOC>